Home » New therapeutic intervention for persons with adrenal tumours and mild autonomous cortisol secretion: the OSI-CORT study » New therapeutic intervention for persons with adrenal tumours and mild autonomous cortisol secretion: the OSI-CORT study

New therapeutic intervention for persons with adrenal tumours and mild autonomous cortisol secretion: the OSI-CORT study

Patient putting pill in mouth to take medication

Research theme

Women’s metabolic health

People involved

Dr Alessandro Prete

Women's Metabolic Health Theme Lead

Status: Ongoing

This experimental medicine study focuses on a novel therapeutic intervention for persons with adrenal tumours and mild autonomous cortisol secretion (MACS), which is an established driver of increased cardiometabolic risk. As part of the OSI-CORT study, persons with MACS will be treated with osilodrostat, an inhibitor of cortisol biosynthesis.

Project aims

We will assess how osilodrostat affects steroid metabolism and the cortisol excess in MACS and – in turn – how this impacts glucose metabolism, muscle function, immune function, and global metabolism of persons living with this condition. The study will begin recruitment in 2024 and is due to complete before the end of the year.

Research projects

The Duchess phenome study

Overproduction of male hormones, androgen excess, is common in children before they enter…

New therapeutic intervention for persons with adrenal…

This experimental medicine study focuses on a novel therapeutic intervention for persons with…

Sleep and mental health during pregnancy

In this study, we explore sleep patterns in mothers during pregnancy and also…